Patients with both chronic obstructive pulmonary disease (COPD) and severe pain are at an almost 40% predicted probability of falling, indicating the potential interaction between the conditions.

Using coronary artery calcium scores alongside cardiovascular risk scores better identifies patients with chronic obstructive pulmonary disease at a high risk for major adverse cardiovascular events.

A Chinese Phase IIb trial of the mAb has already started, with Mabwell also hoping to initiate a Phase IIa trial in the US.

Patients with severe pulmonary hypertension (PH) and chronic obstructive pulmonary disease (COPD) can now be identified using three widely available clinical variables, all of which can be measured ...

Gabapentinoid use in patients with chronic obstructive pulmonary disease (COPD) was associated with a higher risk for severe exacerbations, a population-based cohort study from Canada indicated. Among ...

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced the completion of its Phase IIa clinical study for 9MW1911, a self-developed ...

Integrated primary care services may offer better outcomes in patients living with severe chronic obstructive pulmonary disease (COPD) without increasing costs. The integrated primary care ...

Please provide your email address to receive an email when new articles are posted on . Pulmonary hypertension appears in 25% to 30% of patients with COPD. There are no approved therapies for patients ...

Breathlessness intervention services (BIS), which coach patients to self-manage breathlessness using non-pharmacological ...

In some patients with chronic obstructive pulmonary disease (COPD), type 2 inflammation may increase exacerbation risk and may be indicated by elevated blood eosinophil counts. Dupilumab, a fully ...